Abiopharma

CRISPR THERAPEUTICS AG (CRSP) Reports the reporting period Financial Results CRISPR THERAPEUTICS AG (CRSP) announced its financial results for the period ending the reporting period. Key Financial Highlights:

• Revenue: 10181
• Net Income: Not disclosed
• EPS: Not disclosed
• Cash and equivalents: 291337 Management Commentary: '"The second quarter reflected strong execution across CRISPR Therapeutics' portfolio and platform," said Samarth Kulkarni'
  • targeting cardiovascular and thromboembolic diseases, developed in collaboration with Sirius Therapeutics.•CTX611 (SRSD107), a long-acting siRNA therapeutic targeting Factor XI (FXI), is advancing through a Phase 2 clinical trial in patients undergoing total knee arthroplasty (TKA). The Company expects to provide an update in the second half of 2026
  • targeting angiotensinogen (AGT), has received IND clearance from the FDA. The Company has initiated a Phase 1 clinical trial for patients with refractory hypertension. •CTX460™, targeting SERPINA1 for the treatment of alpha-1 antitrypsin deficiency (AATD), is the first investigational candidate generated from the Company's SyNTase™ editing platform. The Company has initiated a Phase 1 clinical trial for CTX460.•CRISPR Therapeutics' pipeline of preclinical in vivo gene editing candidates includes CTX321™, the Company's next-generation LPA program, which is progressing through IND/CTA-enabling studies. The candidate incorporates an optimized guide RNA that delivered approximately two-fold greater potency in preclinical models, paired with the same LNP delivery system used previously. An Lp(a) program update is anticipated in 2026
  • expected in 2026